---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-022362"
form_type: "8-K"
ticker: "ZVRA"
cik: "0001434647"
company_name: "ZEVRA THERAPEUTICS, INC."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:33:55.627333+00:00"
event_type: "regulatory"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Zevra announces FDA advisory committee meeting for arimoclomol on Aug 2, 2024

## Summary
- FDA's Genetic Metabolic Diseases Advisory Committee (GeMDAC) will review arimoclomol NDA for Niemann-Pick disease type C.
- Meeting scheduled for August 2, 2024; background materials released two business days prior.
- PDUFA action date for arimoclomol is September 21, 2024.
- Arimoclomol is an orally delivered, first-in-class treatment for NPC, a rare genetic disease.
- Zevra CEO highlights opportunity for NPC community to share treatment needs with the advisory committee.

## SEC filing metadata
- accession: 0001437749-24-022362
- form_type: 8-K
- ticker: ZVRA
- cik: 0001434647
- company_name: ZEVRA THERAPEUTICS, INC.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: regulatory
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1434647/000143774924022362/0001437749-24-022362-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1434647/000143774924022362/zvra20240614_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-022362
- JSON: https://secwatch.observer/filing/0001437749-24-022362.json
- Plain text: https://secwatch.observer/filing/0001437749-24-022362.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.